An Explanation of SIR-Spheres

In an interview, Paolo Ghia, MD, PhD, discussed updated data from the phase 2 CAPTIVATE trial of ibrutinib and venetoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma.

In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with myelodysplastic syndrome/myeloproliferative neoplasms and chronic neutrophilic leukemia.

In an interview, Cedric Pobel, MD, further discussed the PEACE-1 trial and its findings.

David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment strategies for TP53-mutant MDS and AML.

Mark A. Lewis, MD, discussed the promise of the ESOPEC and TRANSMET trials and the need for their further investigation.

Amandeep Salhotra, MD, discussed the background and findings from a pilot trial evaluating enasidenib as post-hematopoietic stem cell transplant maintenance therapy for IDH2-mutated acute myeloid leukemia treatment.